These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 15710584)

  • 1. Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders.
    Randi ML; Ruzzon E; Luzzatto G; Tezza F; Girolami A; Fabris F
    Haematologica; 2005 Feb; 90(2):261-2. PubMed ID: 15710584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hydroxyurea-induced leg ulcers in patients with chronic myeloproliferative disorders].
    Olesen LH; Pedersen BB
    Ugeskr Laeger; 2001 Dec; 163(49):6908-11. PubMed ID: 11766504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.
    Nielsen I; Hasselbalch HC
    Am J Hematol; 2003 Sep; 74(1):26-31. PubMed ID: 12949887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicity and side effects of hydroxyurea used for primary thrombocythemia.
    Randi ML; Ruzzon E; Tezza F; Luzzatto G; Fabris F
    Platelets; 2005; 16(3-4):181-4. PubMed ID: 16011962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients.
    Spanoudakis E; Bazdiara I; Kotsianidis I; Margaritis D; Goutzouvelidis A; Christoforidou A; Tsatalas C; Bourikas G
    Ann Hematol; 2009 Jul; 88(7):629-32. PubMed ID: 19096846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
    Pikman Y; Levine RL
    Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leg ulcers in elderly on hydroxyurea: a single center experience in Ph- myeloproliferative disorders and review of literature.
    Ruzzon E; Randi ML; Tezza F; Luzzatto G; Scandellari R; Fabris F
    Aging Clin Exp Res; 2006 Jun; 18(3):187-90. PubMed ID: 16804363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytoses].
    Linkesch W; Gisslinger H; Ludwig H; Flener R; Sinzinger H
    Acta Med Austriaca; 1985; 12(5):123-7. PubMed ID: 3914173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms.
    Caramazza D; Caracciolo C; Barone R; Malato A; Saccullo G; Cigna V; Berretta S; Schinocca L; Quintini G; Abbadessa V; Di Raimondo F; Siragusa S
    Ann Hematol; 2009 Oct; 88(10):967-71. PubMed ID: 19214510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms.
    Hasselbalch HC
    Expert Rev Hematol; 2011 Dec; 4(6):637-55. PubMed ID: 22077528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Thrombinogenesis in chronic myeloproliferative syndromes].
    Rość D; Kremplewska-Nalezyta E; Gadomska G; Kowalewska A; Buczkowska E
    Pol Merkur Lekarski; 2006 Jun; 20(120):717-20. PubMed ID: 17007278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of hydroxyurea on PRV-1 expression in patients with essential thrombocythemia and polycythemia vera.
    Johansson P; Ricksten A; Wasslavik C; Johansson B; Andréasson B
    Haematologica; 2004 Oct; 89(10):1264-6. PubMed ID: 15477215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon in the treatment of myeloproliferative diseases.
    Silver RT
    Semin Hematol; 1990 Jul; 27(3 Suppl 4):6-14. PubMed ID: 2115694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New molecular markers within the chronic myeloproliferative disorders. I: the PRV-1 gene].
    Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
    Ugeskr Laeger; 2006 Sep; 168(39):3295-9. PubMed ID: 17032591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
    Alvarez-Larrán A; Martínez-Avilés L; Hernández-Boluda JC; Ferrer-Marín F; Antelo ML; Burgaleta C; Mata MI; Xicoy B; Martínez-Trillos A; Gómez-Casares MT; Durán MA; Marcote B; Ancochea A; Senín A; Angona A; Gómez M; Vicente V; Cervantes F; Bellosillo B; Besses C
    Ann Hematol; 2014 Dec; 93(12):2037-43. PubMed ID: 24981691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The management of elderly patients with myeloproliferative disorders.
    Tura S
    Hematol Oncol; 1993; 11 Suppl 1():39-41. PubMed ID: 8486340
    [No Abstract]   [Full Text] [Related]  

  • 18. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
    Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
    J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxyurea induced skin ulceration in myeloproliferative disorders.
    McLintock C; Ockelford PA
    Aust N Z J Med; 2000 Jun; 30(3):373-6. PubMed ID: 10914756
    [No Abstract]   [Full Text] [Related]  

  • 20. [Choice of therapy and overall survival in patients with chronic myeloproliferative diseases].
    Rukavitsyn OA; Pop VP; Seriakov AP
    Vopr Onkol; 2004; 50(4):435-9. PubMed ID: 15605767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.